Implication of protein kinase A for a hepato-protective mechanism of milrinone pretreatment

J Surg Res. 2009 Jul;155(1):32-9. doi: 10.1016/j.jss.2008.07.004. Epub 2008 Aug 15.

Abstract

Background: We have previously reported that an increase of adenosine 3',5'-cyclic monophosphate (cAMP) in liver tissue after an administration of milrinone, a phosphodiesterase-3 inhibitor attenuates hepatic warm ischemia-reperfusion injury. The aim of this study was to determine whether cAMP-dependent protein kinase (protein kinase A) activation was involved in the milrinone-induced hepatoprotective effect on an ischemia-reperfusion injury in an in vivo model.

Materials and methods: Male Lewis rats were allocated into 3 groups. In Group M, milrinone was administrated before ischemia; in Group I, a protein kinase A inhibitor, adenosine 3',5'-cyclic monophosphorothioate, 8-bromo-, Rp-isomer, sodium salt (Rp-8-Br-cAMPS), was injected prior to the administration of milrinone; and in Group C, the control group, there was no pretreatment. After pretreatment, all rats were exposed to a 45-min total hepatic inflow occlusion.

Results: After milrinone administration, liver cAMP concentrations and protein kinase A activity ratios were elevated. They protected the liver from ischemia-reperfusion injury. Rp-8-Br-cAMPS suppressed protein kinase A activation without affecting cAMP elevating responses to milrinone. Compared with Group C, hepatocellular necrosis, neutrophil infiltration, and congestion were ameliorated, and serum tumor necrosis factor-alpha, aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase levels were significantly suppressed in Group M. Rp-8-Br-cAMPS canceled this effect, showing histological damages in Group I as severe as in Group C. The levels of tumor necrosis factor-alpha, aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase were the same in Groups C and I.

Conclusions: Activation of protein kinase A might play an important role in the mechanism of milrinone-induced ischemic tolerance in the liver.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alanine Transaminase / blood
  • Animals
  • Aspartate Aminotransferases / blood
  • Blood Pressure
  • Cyclic AMP / metabolism
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors
  • Cyclic AMP-Dependent Protein Kinases / metabolism*
  • Heart Rate
  • Lactate Dehydrogenases / blood
  • Liver / metabolism
  • Liver / pathology
  • Liver Diseases / pathology
  • Liver Diseases / prevention & control*
  • Male
  • Milrinone / pharmacology*
  • Milrinone / therapeutic use
  • Phosphodiesterase Inhibitors / pharmacology*
  • Phosphodiesterase Inhibitors / therapeutic use
  • Pulse
  • Rats
  • Rats, Inbred Lew
  • Reperfusion Injury / pathology
  • Reperfusion Injury / prevention & control*
  • Tumor Necrosis Factor-alpha / blood

Substances

  • Phosphodiesterase Inhibitors
  • Tumor Necrosis Factor-alpha
  • Cyclic AMP
  • Lactate Dehydrogenases
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • Cyclic AMP-Dependent Protein Kinases
  • Milrinone